Treatment with JQ1 resulted in genome‐wide downregulation of Myc‐dependent target genes, reduced proliferation and had anti‐cancer properties in a mouse model of multiple myeloma, a Myc‐dependent hematologic malignancy, suggesting that JQ1 may perform similarly in mouse models of colorectal cancer. The gene discussed is MYC; the disease is plasma cell myeloma.